Transplanting HCV-infected kidneys into uninfected recipients

New England Journal of Medicine

Volumn 377, Issue 11, 2017, Pages 1104-1105

  Martins, Paulo N ^a   Movahedi, Babak ^a   Bozorgzadeh, Adel ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

DRUG RESPONSE; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY TRANSPLANTATION; LETTER; MORTALITY; PRIORITY JOURNAL; VIROLOGY; KIDNEY;

HEPATITIS C; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION;

EID: 85029429134     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1709315     Document Type: Letter

References (4)

1. Bowring MG, Kucirka LM, Massie AB, et al. Changes in utilization and discard of hepatitis C-infected donor livers in the recent era. Am J Transplant 2017;17:519-27.
2. Coilly A, Samuel D. Pros and cons: usage of organs from donors infected with hepatitis C virus — revision in the direct-acting antiviral era. J Hepatol 2016;64:226-31.
3. Levitsky J, Verna EC, O’Leary JG, et al. Perioperative ledipasvir–sofosbuvir for HCV in liver-transplant recipients. N Engl J Med 2016;375:2106-8.
4. Suryaprasad A, Basavaraju SV, Hocevar SN, et al. Transmission of hepatitis C virus from organ donors despite nucleic acid test screening. Am J Transplant 2015;15:1827-35.